BiotechTube

VX-864

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alpha-1 Antitrypsin Deficiency

Conditions

Alpha-1 Antitrypsin Deficiency

Trial Timeline

Feb 23, 2023 → Aug 19, 2024

NCT ID
NCT05643495

About VX-864

VX-864 is a phase 2 stage product being developed by Vertex Pharmaceuticals for Alpha-1 Antitrypsin Deficiency. The current trial status is terminated. This product is registered under clinical trial identifier NCT05643495. Target conditions include Alpha-1 Antitrypsin Deficiency.

What happened to similar drugs?

0 of 2 similar drugs in Alpha-1 Antitrypsin Deficiency were approved

Approved (0) Terminated (0) Active (2)
🔄Alpha-1 MPGrifolsPhase 3
🔄Alpha-1 MPGrifolsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05643495Phase 2Terminated

Competing Products

13 competing products in Alpha-1 Antitrypsin Deficiency

See all competitors
ProductCompanyStageHype Score
Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) PlaceboNovartisPhase 2
27
VX-668 + PlaceboVertex PharmaceuticalsPhase 1
29
ALN-AAT02 + Placebo + ALN-AAT02Alnylam PharmaceuticalsPhase 1/2
21
ARC-AAT Injection + DiphenhydramineArrowhead PharmaceuticalsPhase 1
18
ARC-AAT InjectionArrowhead PharmaceuticalsPhase 2
24
Alpha-1 MPGrifolsPhase 3
44
Alpha-1 MPGrifolsPhase 3
41
WVE-006WaVe Life SciencesPhase 1
23
WVE-006WaVe Life SciencesPhase 1/2
33
INBRX-101/rhAAT-FcInhibrx BiosciencesPhase 1
23
Kamada-AAT for Inhalation, 80mg + Placebo + Kamada-AAT for Inhalation, 160mgKamadaPhase 2
29
KRRO-110Korro BioPhase 1/2
26
Alvelestat (MPH966)Mereo BioPharmaPhase 2
25